Source: Virtual Congress 2021 – Highlights from the JAMA Network on idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and lung cancer screening



Rating:

Share or cite this content

Citations should be made in the following way:
A. Wilson (Norwich (Norfolk), United Kingdom). Role of the microbiome and antibiotic therapy in IPF. Virtual Congress 2021 – Highlights from the JAMA Network on idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and lung cancer screening

Member's Comments

No comment yet.

Related content which might interest you: Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens Source: Eur Respir Rev, 28 (152) 190041; 10.1183/16000617.0041-2019 Year: 2019 What is the role of prophylactic antibiotic therapy in chronic bronchitis or COPD? Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 Perspectives on antibiotic treatment of NTM pulmonary disease Source: Eur Respir Monogr 2017; 75: 245-252 Year: 2017 Anti-IL-5 therapy and the airway microbiome in asthma. Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Co-occurrence analysis relates a macrolide resistome to the pulmonary microbiome in chronic respiratory disease Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Inhaled corticosteroids, bacterial load and the lung microbiome in COPD Source: International Congress 2019 – Exploring the link between inhaled corticosteroids and respiratory infection Year: 2019 Measuring adherence to therapy in airways disease Source: Breathe, 17 (2) 210037; 10.1183/20734735.0037-2021 Year: 2021 The microbiome in IPF Source: International Congress 2014 – ERS/NEJM joint lunchtime session "The changing landscape of idiopathic pulmonary fibrosis (IPF)" Year: 2014 Switching of antimicrobial agents in the therapy of community acquired pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 The lung microbiota changes associated with inhaled corticosteroid and azithromycin in murine model of COPD Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018 Treatment outcome of combination antibiotic therapy including clarithromycin for Mycobacterium avium complex pulmonary disease Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010 The pulmonary microbiome and immunological activity in IPF patients. Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Long-term macrolide therapy for non-CF bronchiectasis Source: Annual Congress 2013 –ERS/JAMA Lunchtime session "Advances in IPF, bronchiectasis and sarcoidosis" Year: 2013 Role of inhaled corticosteroids on recurrent bronchial infection by potentially pathogenic bacteria in patients with COPD Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Combination antibiotic therapy and synergy in HAP and VAP Source: Eur Respir Monogr 2017; 75: 302-311 Year: 2017 Azithromycin, a novel maintenance therapy in patients with chronic non-CF suppurative lung disease Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011 Periodical therapy with antibiotics preserves lung function in patients with bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy Source: Eur Respir J 2006; 28: Suppl. 50, 736s Year: 2006